Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Analysts rate Silence Therapeutics “Moderate Buy.” Of six analysts, four recommend buying, one strongly recommends buying, and one rates the stock a sell; the average 12-month price target is $53.50.
• Institutional ownership is substantial at 98.73%. Several funds recently increased or initiated positions, including ADAR1 Capital Management, which raised its stake by 628.2%.
• SLN shares opened at $11.22, compared with a one-year range of $4.19 to $17.58. The company reported a quarterly loss of $0.26 per share, missing the $0.14-per-share consensus estimate.

Shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six analysts that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $53.50.

SLN has been the topic of several recent analyst reports. HC Wainwright restated a "buy" rating and issued a $75.00 target price on shares of Silence Therapeutics in a report on Wednesday, June 17th. Cantor Fitzgerald assumed coverage on Silence Therapeutics in a report on Wednesday, June 24th. They set an "overweight" rating for the company. Morgan Stanley lifted their price objective on Silence Therapeutics from $25.00 to $32.00 and gave the stock an "overweight" rating in a research report on Tuesday, August 11th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Silence Therapeutics in a research note on Friday, July 17th.

Hedge Funds Weigh In On Silence Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of SLN. 5AM Venture Management LLC acquired a new stake in shares of Silence Therapeutics during the 2nd quarter worth approximately $5,228,676. SG Americas Securities LLC boosted its stake in Silence Therapeutics by 11.8% during the first quarter. SG Americas Securities LLC now owns 286,698 shares of the company's stock worth $1,511,000 after acquiring an additional 30,358 shares in the last quarter. Ishara Investments LP acquired a new stake in Silence Therapeutics in the fourth quarter worth $1,459,000. Squarepoint Ops LLC grew its holdings in Silence Therapeutics by 29.6% in the second quarter. Squarepoint Ops LLC now owns 115,918 shares of the company's stock worth $1,273,000 after purchasing an additional 26,449 shares during the period. Finally, ADAR1 Capital Management LLC increased its stake in Silence Therapeutics by 628.2% in the first quarter. ADAR1 Capital Management LLC now owns 172,157 shares of the company's stock valued at $907,000 after purchasing an additional 148,514 shares in the last quarter. 98.73% of the stock is currently owned by institutional investors.

Silence Therapeutics Price Performance

Shares of SLN stock opened at $11.22 on Friday. The business's 50 day simple moving average is $12.76 and its 200 day simple moving average is $9.18. Silence Therapeutics has a one year low of $4.19 and a one year high of $17.58. The stock has a market capitalization of $675.56 million, a PE ratio of -8.77 and a beta of 1.45.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.12). Silence Therapeutics had a negative return on equity of 106.94% and a negative net margin of 8,943.86%. As a group, research analysts expect that Silence Therapeutics will post -1.03 earnings per share for the current year.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a biotechnology company focused on developing medicines that use small interfering RNA (siRNA) to selectively reduce the production of disease-related proteins. Its proprietary mRNAi GOLD platform is designed to identify and silence specific messenger RNA targets, with the aim of producing durable effects from infrequent dosing.

The company's pipeline includes zerlasiran, formerly known as SLN360, an investigational therapy designed to reduce production of lipoprotein(a), a genetically determined risk factor associated with cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.